Bionet-Asia Co. Ltd., of Bangkok, provided an update on the company's lead vaccine program at BioJapan 2014, in Yokohama, Japan. The current phase I/II trial in Thailand showed that the vaccine is safe and immunogenic and full results will soon be published in a peer-reviewed journal, Bionet said.